Table 2.

Safety summary; No of patients. No grade 3–4 AE observed. One case of pneumonitis, in which an immune-mediated pneumonitis could not be ruled out.

	Any toxicitiy		Monalizumb-related AE
	Grade 1-2	Grade ≥3	Grade 1-2	Grade ≥3
Diarrhea	2 (14%)		2 (14%)
Fatigue	2 (14%)		2 (14%)
Allergic reaction	1 (7%)		1 (7%)
Bladder infection	1 (7%)
Dyspnea	1 (7%)
Headache	1 (7%)		1 (7%)
Infections and infestations, other	1 (7%)
Nausea	1 (7%)		1 (7%)
Peripheral motor neuropathy	1 (7%)
Pneumonitis	1 (7%)	1 (7%)	1 (7%)	1 (7%)
Soft tissue infection	1 (7%)
Weight loss	1 (7%)		1 (7%)